Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure I: Introduction01:27

Heart Failure I: Introduction

Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fundamentals of Acute Pericarditis: State of the Art.

Arquivos brasileiros de cardiologia·2026
Same author

Cardiac Amyloidosis and SGLT2 Inhibitors: Signal, Hope, and the Need for Randomized Evidence.

Arquivos brasileiros de cardiologia·2026
Same author

Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025.

Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia·2025
Same author

Position Statement on Cardiometabolic Health Across the Woman's Life Course - 2025.

Arquivos brasileiros de cardiologia·2025
Same author

Patisiran in the Treatment of Cardiac Amyloidosis: Good for the World and Good for Brazil.

Arquivos brasileiros de cardiologia·2025
Same author

Acute Heart Failure in Patients with Chagas Cardiomyopathy: Results of the I Brazilian Heart Failure Registry (BREATHE).

Arquivos brasileiros de cardiologia·2025

Related Experiment Videos

Immune-inflammatory activation in heart failure.

Angelo Michele de Candia1, Humberto Villacorta, Evandro Tinoco Mesquita

  • 1Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói, RJ, Brasil. angelodicandia@yahoo.com.br

Arquivos Brasileiros De Cardiologia
|October 2, 2007
PubMed
Summary

Heart failure (HF) involves chronic immune-inflammatory activation, with elevated cytokines correlating to disease severity. Targeting this inflammatory loop is crucial for developing effective new therapies for heart failure patients.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Immunology
  • Pathophysiology

Background:

  • Heart failure (HF) is increasingly recognized as a condition involving chronic immune-inflammatory activation.
  • Elevated circulating and cardiac cytokine levels in HF patients correlate with disease severity.
  • This inflammatory state contributes to endothelial dysfunction, oxidative stress, anemia, and muscle wasting.

Purpose of the Study:

  • To review the evidence linking immune-inflammatory activation to heart failure progression.
  • To explore the multifaceted relationship between inflammation and HF decompensation.
  • To highlight the need for a deeper understanding to develop novel therapeutic strategies.

Main Methods:

  • Review of experimental and clinical evidence on immune-inflammatory pathways in HF.
  • Analysis of cytokine profiles in HF patients and their correlation with disease severity.
  • Examination of the role of various tissues in perpetuating the inflammatory state.

Main Results:

  • A significant body of evidence supports a persistent immune-inflammatory activation in HF.
  • Cytokines are implicated in key pathological processes including endothelial dysfunction and myocyte apoptosis.
  • While biomarkers show prognostic value, clinical trials modulating the inflammatory loop have yielded limited success.

Conclusions:

  • Immune-inflammatory activation is a central component of the pathophysiology of heart failure.
  • Understanding the complex interplay between inflammation and HF decompensation is critical.
  • Further research is needed to identify effective therapeutic targets within the immune-inflammatory network for HF.